Publications scientifiques en 2026

Depuis le 23/02/2026
  1. Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study.
    Néant N, Lê MP, Bouchet S, Lagoutte-Renosi J, Grégoire M, Parant F, Venisse N, Lalanne S, Lemaitre F, Muret P, Renou Q, Destere A, Gandia P, Flandre P, Peytavin G, Solas C; ANRS-MIE-CARLAPOP Study Group.
    Clin Infect Dis. 2026
  2. Appropriateness of oxycodone use for acute pain in surgical and obstetric departments using a clinical data warehouse.
    Xuereb F, Trin K, Griffier R, Salvo F, Frasca M, Noize P, Bezin J, Pariente A.
    Br J Clin Pharmacol. 2026
  3. The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine.
    Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, Pariente A, Raschi E.
    Clin Pharmacol Ther. 2026
  4. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet É, Le Jeunne C.
    Therapie. 2026
  5. Standardizing and Comparing Management Recommendations for Potential Drug-Drug Interactions Across Different Interaction Checkers.
    Crupi L, Letinier L, Jouhet V, Cossin S, Pariente A, Mathieu C, Martin GL, Konschelle F, Rouanet J, Carollo M, Trifirò G, Esposito E, Salvo F.
    Drug Saf. 2026
  6. How can the level of health product education (literacy) be raised among the general public?
    Locher C, Manaud N, Molimard M, Cassé-Perrot C, Cracowski JL, Di Palma C, Duchossoy L, Gatignol C, Goldgewicht A, Hertel O, Lacombe K, Lacroix C, Moreau-Chevrolet P, Quelet S, Rivière P, Lagouanelle MC, Micallef J.
    Therapie. 2026
  7. Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system.
    Velişcu EM, Cagnotta C, Sullo MG, Anatriello A, Salvo F, Scavone C.
    Front Drug Saf Regul. 2026
  8. Drugs associated with generalized non-allergic pruritus: A World Health Organization pharmacovigilance database analysis.
    Kondor L, Cicala G, Salvo F, Clabecq C, Misery L, Brenaut E, Gourier G, Le Garrec R.
    J Am Acad Dermatol. 2026
  9. Coprescription of antipsychotics and benzodiazepines at hospital discharge.
    Demourgues M, Richaud A, Thiec J, Debruyne AL, Guillemin S, Tournier M, Salvo F, Queuille E.
    Encephale. 2026
  10. Language models in pharmacovigilance: Applications, promises and limits.
    Salvo F, Crupi L, Cholle C.
    Therapie. 2026
  11. Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.
    Munech-Herran M, Moysan V, Lescarret B, Mathieu C, Pariente A, Rousselot N.
    Br J Clin Pharmacol. 2026
  12. SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study.
    Demourgues M, Bezin J, Griffier R, Pariente A, Noize P, de Germay S.
    Fundam Clin Pharmacol. 2026